Compare AbbVie Inc (ABBV) vs iShares TIPS Bond ETF (TIP) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

TIP trades at $108.49 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators remain neutral. The stock faces resistance at $109 with support at $108. Recent dividend announcements for 2026 provide income visibility, but key financial ratios are unavailable for fundamental assessment.

The outlook remains cautious due to bearish technical signals and lack of fundamental data. Dividend payments offer some stability, but investors need updated financial metrics to assess valuation. Market sentiment reflects broader bond market uncertainties and Federal Reserve policy concerns affecting income-focused equities.